Beijing Tongrentang Third Quarter 2024 Earnings: EPS Misses Expectations

Beijing Tongrentang (SHSE:600085) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥4.06b (up 2.4% from 3Q 2023).
• Net income: CN¥329.1m (down 19% from 3Q 2023).
• Profit margin: 8.1% (down from 10% in 3Q 2023). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.24 (down from CN¥0.29 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Tongrentang EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 19%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 1.5% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Beijing Tongrentang (1 doesn't sit too well with us!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.